Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Scandinavian Journal of Pain

Official Journal of the Scandinavian Association for the Study of Pain

Editor-in-Chief: Breivik, Harald


CiteScore 2017: 0.84

SCImago Journal Rank (SJR) 2017: 0.401
Source Normalized Impact per Paper (SNIP) 2017: 0.452

Online
ISSN
1877-8879
See all formats and pricing
More options …
Volume 17, Issue 1

Issues

Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of L-4-chlorokynurenine in healthy volunteers

Mark Wallace
  • Corresponding author
  • Department of Anesthesiology, University of California San Diego, 9500 Gilman Drive, MS 0898, La Jolla, CA 92093-0898, La Jolla, United States
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Alexander White / Kathy A. Grako / Randal Lane / Allen (Jo) Cato / H. Ralph Snodgrass
Published Online: 2017-10-01 | DOI: https://doi.org/10.1016/j.sjpain.2017.05.004

Graphical Abstract

Abstract

Background and aims

Neuropathic pain is a significant medical problem needing more effective treatments with fewer side effects. Overactive glutamatergic transmission via N-methyl-D-aspartate receptors (NMDARs) are known to play a role in central sensitization and neuropathic pain. Although ketamine, a NMDAR channel-blocking antagonist, is often used for neuropathic pain, its side-effect profile and abusive potential has prompted the search for a safer effective oral analgesic. A novel oral prodrug, AV-101 (L-4 chlorokynurenine), which, in the brain, is converted into one of the most potent and selective GlyB site antagonists of the NMDAR, has been demonstrated to be active in animal models of neuropathic pain. The two Phase 1 studies reported herein were designed to assess the safety and pharmacokinetics of AV-101, over a wide dose range, after daily dosing for 14-days. As secondary endpoints, AV-101 was evaluated in the capsaicin-induced pain model.

Methods

The Phase 1A study was a single-site, randomized, double-blind, placebo-controlled, single oral ascending dose (30–1800 mg) study involving 36 normal healthy volunteers. The Phase 1B study was a single-site randomized, double-blind, placebo-controlled, study of multiple ascending doses (360, 1080, and 1440mg/day) of AV-101 involving 50 normal healthy volunteers, to whom AV-101 or placebo were administered orally daily for 14 consecutive days. Subjects underwent PK blood analyses, laboratory assessments, physical examination, 12-lead ECG, ophthalmological examination, and various neurocognitive assessments. The effect of AV-101 was evaluated in the intradermally capsaicin-induced pain model (ClinicalTrials.gov Identifier: NCT01483846).

Results

Two Phase 1, with an aggregate of 86 subjects, demonstrated that up to 14 days of oral AV-101, up to 1440mg per day, was safe and very well tolerated with AEs quantitively and qualitatively like those observed with placebo. Mean half-life values of AV-101 were consistent across doses, ranging with an average of 1.73 h, with the highest Cmax (64.4 μg/mL) and AUC0-t (196 μgh/mL) values for AV-101 occurring in the 1440-mg dose group. In the capsaicin induce-pain model, there was no significant change in the area under the pain time curve (AUPC) for the spontaneous pain assessment between the treatment and the placebo groups on Day 1 or 14 (the primary endpoint). In contrast, there were consistent reductions at 60–180 min on Day 1 after dosing for allodynia, mechanical hyperalgesia, heat hyperalgesia, and spontaneous pain, and on Day 14 after dosing for heat hyperalgesia.

Conclusions

Although, AV-101 did not reach statistical significance in reducing pain, there were consistent reductions, for allodynia pain and mechanical and heat hyperalgesia. Given the excellent safety profile and PK characteristics demonstrated by this study, future clinical trials of AV-101 in neuropathic pain are justified.

Implications

This article presents the safety and PK of AV-101, a novel oral prodrug producing a potent and selective GlyB site antagonist of the NMDA receptor. These data indicate that AV-101 has excellent safety and PK characteristics providing support for advancing AV-101 into Phase 2 studies in neuropathic pain, and even provides data suggesting that AV-101 may have a role in treating depression.

This article offers supplementary material which is provided at the end of the article.

Keywords: 7-Chlorokynurenic acid; L-4-Chlorokynurenine; Glycine site antagonist; Pain; NMDA receptor

References

About the article

Received: 2017-02-24

Revised: 2017-05-16

Accepted: 2017-05-17

Published Online: 2017-10-01

Published in Print: 2017-10-01


Funding: This work was funded by the following NIH grants: NIDA 1R43DA018515 and 2R44DA018515; and NINDS R43NS047808.

Conflict of interest: R. Snodgrass and A. Cato have equity positions in VistaGen Therapeutics, which has commercial rights to AV-101 (L-4- chlorokynurenine). K. Grako, R. Lane and A. Cato are employees of Cato Research, which has drug development contracts with Vista-Gen. M. Wallace and A. White have no conflicts or competing interests.

Ethical issue statement: This study was approved by the University of California San Diego Institutional Review Board, and informed consent was obtained from each subject prior to entering the study.


Citation Information: Scandinavian Journal of Pain, Volume 17, Issue 1, Pages 243–251, ISSN (Online) 1877-8879, ISSN (Print) 1877-8860, DOI: https://doi.org/10.1016/j.sjpain.2017.05.004.

Export Citation

© 2017 Scandinavian Association for the Study of Pain.Get Permission

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Bashkim Kadriu, Laura Musazzi, Ioline D Henter, Morgan Graves, Maurizio Popoli, and Carlos A Zarate
International Journal of Neuropsychopharmacology, 2018
[3]
Vera A. Alferova, Maxim V. Shuvalov, Taisiya A. Suchkova, Gleb V. Proskurin, Ilya O. Aparin, Eugene A. Rogozhin, Roman A. Novikov, Pavel N. Solyev, Alexey A. Chistov, Alexey V. Ustinov, Anton P. Tyurin, and Vladimir A. Korshun
Amino Acids, 2018

Comments (0)

Please log in or register to comment.
Log in